Mahesh Shivhare

443 total citations
14 papers, 256 citations indexed

About

Mahesh Shivhare is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mahesh Shivhare has authored 14 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mahesh Shivhare's work include HER2/EGFR in Cancer Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Advanced Breast Cancer Therapies (4 papers). Mahesh Shivhare is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Advanced Breast Cancer Therapies (4 papers). Mahesh Shivhare collaborates with scholars based in United Kingdom, United States and Switzerland. Mahesh Shivhare's co-authors include Zbigniew Nowecki, Christian Schem, Sarah Heeson, Whitney P. Kirschbrown, Seock‐Ah Im, Antoinette R. Tan, Michelino De Laurentiis, Tanja Badovinac Črnjević, Jean‐Yves Pierga and Rámón Colomer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mahesh Shivhare

13 papers receiving 249 citations

Peers

Countries citing papers authored by Mahesh Shivhare

Since Specialization

Citations

This map shows the geographic impact of Mahesh Shivhare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mahesh Shivhare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mahesh Shivhare more than expected).

Fields of papers citing papers by Mahesh Shivhare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mahesh Shivhare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mahesh Shivhare. The network helps show where Mahesh Shivhare may publish in the future.

Co-authorship network of co-authors of Mahesh Shivhare

This figure shows the co-authorship network connecting the top 25 collaborators of Mahesh Shivhare. A scholar is included among the top collaborators of Mahesh Shivhare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mahesh Shivhare. Mahesh Shivhare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Abstract PS4-06: HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial 2025 ·Clinical Cancer Research ·(unknown), Fara Brasó‐Maristany, Guillermo Villacampa, Eva Ciruelos, Mercedes Marín‐Aguilera, Patricia Galván, Sanne de Haas, Eleonora Restuccia, Mahesh Shivhare, Laia Paré, Wesley Buckingham, Joel S. Parker, Ana Vivancos, Charles M. Perou, Patricia Villagrasa, Julia Maués, Aleix Prat, Sandra M. Swain	0
2	Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer 2023 ·Cancer Research ·Elgene Lim, (unknown), Aditya Bardia, Joohyuk Sohn, Heather M. Moore, Mahesh Shivhare, (unknown), (unknown), (unknown), (unknown)	2
3	Abstract OT2-03-01: heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer 2023 ·Cancer Research ·Sherko Küemmel, Catherine Harper‐Wynne, (unknown), Fábio Franke, Michelino De Laurentiis, Eva Schumacher-Wulf, Daniel Eiger, Sarah Heeson, Mahesh Shivhare, Eleonora Restuccia, Joyce O’Shaughnessy	2
4	211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study 2022 ·Annals of Oncology ·M. Martín Jiménez, Elgene Lim, (unknown), Amit Bardia, Jun Wu, Q. Zhang, Zbigniew Nowecki, (unknown), Р. Р. Сафин, S-B. Kim, Christian Schem, Alberto J. Montero, (unknown), (unknown), Mahesh Shivhare, Monika Patre, (unknown), (unknown), (unknown), Joohyuk Sohn	43
5	Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma 2022 ·Blood Advances ·Anas Younes, John M. Burke, Bruce D. Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina Nielsen, Gila Sellam, Jeff P. Sharman	14
6	Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma 2022 ·Journal of Cancer Research and Clinical Oncology ·Max S. Topp, Herbert Eradat, Axel Florschütz, Andreas Hochhaus, Tomasz Wróbel, Jan Walewski, Wanda Knopińska‐Posłuszny, Abraham S. Kanate, Ewa Lech‐Marańda, Uta Brunnberg, Surya Chitra, Tina Nielsen, Gila Sellam, Mahesh Shivhare, Izidore S. Lossos	8
7	Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma 2022 ·Blood Advances ·Anas Younes, John M. Burke, Catherine Diefenbach, Silvia Ferrari, Cyrus Khan, Jeff P. Sharman, Monica Tani, Chaitra S. Ujjani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina Nielsen, Gila Sellam, Michael Gilbertson	5
8	Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma: Results from a Phase 1b Study 2021 ·Clinical Lymphoma Myeloma & Leukemia ·M. Lia Palomba, Brian G. Till, Steven I. Park, Franck Morschhauser, Guillaume Cartron, Reinhard Marks, Mahesh Shivhare, Wan‐Jen Hong, Aparna Raval, Alice Chien Chang, Elicia Penuel, Leslie Popplewell	13
9	46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study 2021 ·Annals of Oncology ·S-A. Im, Antoinette R. Tan, André Mattar, Rámón Colomer, (unknown), Zbigniew Nowecki, Michelino De Laurentiis, J-Y Pierga, Kyung Hae Jung, Christian Schem, (unknown), Tanja Badovinac Črnjević, Sarah Heeson, Mahesh Shivhare, (unknown), Eleonora Restuccia, Christian Jackisch	4
10	Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Maria Lia Palomba, Guillaume Cartron, Leslie Popplewell, Vincent Ribrag, Jason R. Westin, Ling‐Yuh Huw, Shefali Agarwal, Mahesh Shivhare, Wan‐Jen Hong, Aparna Raval, Alice Chien Chang, Elicia Penuel, Franck Morschhauser	29
11	acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician’s choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC). 2021 ·Journal of Clinical Oncology ·Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor, Mahesh Shivhare, Graham Ross, Monika Patre, (unknown), Maria Louka, Joohyuk Sohn	4
12	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study 2020 ·The Lancet Oncology ·Antoinette R. Tan, Seock‐Ah Im, André Mattar, Rámón Colomer, (unknown), Zbigniew Nowecki, Michelino De Laurentiis, Jean‐Yves Pierga, Kyung Hae Jung, Christian Schem, (unknown), Tanja Badovinac Črnjević, Sarah Heeson, Mahesh Shivhare, Whitney P. Kirschbrown, Eleonora Restuccia, Christian Jackisch	104
13	Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study 2020 ·Cancer Research ·Antoinette R. Tan, Seock‐Ah Im, André Mattar, Rámón Colomer, (unknown), Zbigniew Nowecki, Michelino De Laurentiis, Jean‐Yves Pierga, Kyung Hae Jung, Christian Schem, Sarah Heeson, Mahesh Shivhare, Whitney P. Kirschbrown, Eleonora Restuccia, Tanja Badovinac Črnjević, Christian Jackisch	8
14	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study 2019 ·Blood ·Anas Younes, John M. Burke, Bruce D. Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, (unknown), Aparna Raval, Mahesh Shivhare, Tina Nielsen, Gila Sellam, Jeff P. Sharman	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact